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Abstract: Maximizing space–time yields (STY) of biocatalytic flow processes is essential for the
establishment of a circular biobased economy. We present a comparative study in which different
biocatalytic flow reactor concepts were tested with the same enzyme, the (R)-selective alcohol
dehydrogenase from Lactobacillus brevis (LbADH), that was used for stereoselective reduction of
5-nitrononane-2,8-dione. The LbADH contained a genetically encoded streptavidin (STV)-binding
peptide to enable self-immobilization on STV-coated surfaces. The purified enzyme was immobilized
by physisorption or chemisorption as monolayers on the flow channel walls, on magnetic microbeads
in a packed-bed format, or as self-assembled all-enzyme hydrogels. Moreover, a multilayer biofilm
with cytosolic-expressed LbADH served as a whole-cell biocatalyst. To enable cross-platform
comparison, STY values were determined for the various reactor modules. While mono- and
multilayer coatings of the reactor surface led to STY < 10, higher productivity was achieved with
packed-bed reactors (STY ≈ 100) and the densely packed hydrogels (STY > 450). The latter modules
could be operated for prolonged times (>6 days). Given that our approach should be transferable
to other enzymes, we anticipate that compartmentalized microfluidic reaction modules equipped
with self-immobilizing biocatalysts would be of great utility for numerous biocatalytic and even
chemo-enzymatic cascade reactions under continuous flow conditions.
Keywords: enzymes; flow biocatalysis; immobilization techniques; stereoselective reactions;
biomaterials; micro reactors
1. Introduction
Enzymes are highly efficient and specific catalysts, continuously changed by nature through
evolution since the beginning of life. Their industrial implementation is expected to have an enormous
impact on the emergence of a biobased circular economy or “bioeconomy” [1,2]. To establish
the efficient use of renewable biomass as an alternative to petrochemical synthesis for sustainable
production processes in the future, the barrier of economic viability of enzyme processes has to
be overcome. While recent progress in the field of industrial biocatalysis for the production of
pharmaceutical drugs, such as Montelukast (Singulair®by MSD) [3], Atorvastatin (Sortis®, Atorvalan®,
or Lipitor®by Pfizer) [4], Ipatasertib (Roche) [5], and Sitagliptin (MSD) [6], clearly indicates the
feasibility of this approach, further improvement of such processes will crucially depend on the
availability of flexible technical production platforms. In view of these developments, miniaturized
flow reactors that enable enzymatic multistep reactions are currently attracting much attention [7–13].
Facilitating the production of value-added molecules by conventional organic syntheses reaction
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cascades can be realized by the precise arrangement of spatially separated sequential transformations
within individual reaction vessels that are fluidically coupled with each other. In classical synthetic
organic chemistry, this approach is known as “flow chemistry”. It takes advantage of a high
degree of control over temperature profiles and diffusion-based mixing along with machine-assisted
automation [14] and has recently yielded impressive synthesis campaigns for small molecules [15–17].
In contrast to flow chemistry, and despite the high attractiveness of enzymatic transformations,
continuous “flow biocatalysis” is still in its infancy [13,18–26].
One of the major challenges that hampers the broad application of biocatalytic processes
in flow systems stems from a limited number of appropriate methods for the immobilization of
delicate enzymes, which are usually more demanding than conventional organometallic catalysts [27].
Common approaches for enzyme immobilization inside microstructured flow channels include
non-specific physisorption and chemical cross-linking, as well as more sophisticated and often more
efficient methods that are based on directional bioorthogonal one-point immobilization strategies,
mediated by genetically encoded immobilization tags [28]. While these methods have proven their
applicability [13,20,21,29–31], another important problem stems from the limitation on the amount
of immobilized biocatalyst which is determined by the effective surface area. This issue has, for
example, been addressed by the use of pseudo-3D interfacial layers comprising synthetic polymers
or micro-/nanoparticles that increase the number of binding sites and, thus, the loading capacity for
enzymes [32–34] with a concomitant maximization of the reactor space–time yields. These approaches
are not limited to purified enzymes as whole-cell biocatalysts can also be applied to build up
3-dimensional production systems, as exemplified by productive biofilms for continuous production
processes of fine chemicals [35]. However, comparative studies utilizing the same enzyme, either in a
purified formulation or else expressed as whole-cell biocatalysts, in different flow reactor setups are
still lacking.
To further contribute to the systematic development of flow biocatalysis, we describe here a
comprehensive comparison of five different biocatalytic flow-reactor concepts that are based on the
same enzyme, the industrial relevant and intensively studied (R)-selective alcohol dehydrogenase
(ADH, EC 1.1.1.2) from Lactobacillus brevis ATCC 14869 (LbADH) (Taxonomy ID: 649758) [36]. A typical
flow biocatalytic work station used for this study consists of syringe pumps connected to a chip micro
reactor harboring the biocatalyst and an automated outflow collector for subsequent sample analysis
(Figure 1a). Depending on the requirements of the individual biocatalyst, meander-shaped flow
channels were employed for physisorbed or chemically immobilized enzymes, as well as productive
biofilms (Figure 1b), whereas linear flow channels were used for packed-bed reactors harboring
enzyme-functionalized magnetic particles (Figure 1c) or self-assembling all-enzyme hydrogels
(Figure 1d). To enable cross-platform assessment and comparison of the productivity of the various
flow biocatalyst modules, differences in reactor volume and flow rates were compensated for by the
determination of STY. To account for variations in reactor volume due to variable quantities of biomass
and carrier/adsorbed materials, space–time yields were calculated on the basis of the reactor geometry.
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Figure 1. Setup for continuous flow biocatalysis using microfluidic chip reactors. (a) Overview of the
microfluidic system with photo and scheme of (b) polydimethylsiloxane (PDMS) chip with meandering
flow path containing a productive Escherichia coli biofilm. (c) polymethylmethacrylate (PMMA) chip
with permanent magnets arranged beneath the flow channel holding enzyme-functionalized magnetic
particles (brown). (d) PDMS chip with pure all-enzyme hydrogel in a straight flow path.
2. Results and Discussion
To explore and validate the utility of the different reactor modules for immobilization
of the (R)-selective alcohol dehydrogenase LbADH, we used the prochiral CS-symmetrical
5-nitrononane-2,8-dione (NDK) 1 (Scheme 1), which can be reduced, depending on the ADH
selectivity, either on one or both of the two carbonyl functions to create the hydroxyketones 2
or diols 3, respectively [37]. Since all stereoisomeric products can be readily analyzed by chiral
HPLC, the two-step enantiogroup-differentiating reduction of the prochiral NDK 1 is ideally suited
to characterizing the biocatalytic activity of a given flow biocatalysis reactor. To enable a simple
downstream process, the LbADH sequence was N-terminally extended by the 39 amino acid
streptavidin-binding peptide (SBP) tag [38] that binds with high affinity (KD = 2.5 nM) to the protein
streptavidin (STV) [39], enabling a simple one-step purification. The LbADH–SBP was overexpressed
in Escherichia coli and purified to homogeneity using STV-affinity chromatography. Details on the
reaction kinetics and stereoselectivity for the reduction of the NDK 1 substrate of the LbADH–SBP
were recently described [30]. As shown in Scheme 1, LbADH–SBP converts NDK 1 in a highly
stereoselective manner to (R)-syn/anti-hydroxyketones 2c/d (e.r. > 99:1; d.r. ~ 60:40) and then further
to (R,R)-configured pseudo C2-diol 3d (d.r. 99:1).
To cope with the high demand for the expensive cofactor, nicotinamide adenine dinucleotide
phosphate (NADPH), three different strategies were used in this study (Scheme 1). The simplest
approach used the ability of LbADH to regenerate its own cosubstrate through the oxidation of
2-propanol to acetone [36] (Scheme 1, I). However, the LbADH productivity was found to be lower due
to additional oxidation of 2-propanol to acetone [30]. Therefore, employment of an additional enzyme
for the regeneration of the cofactor was found to be more effective. In the case of whole-cell biocatalysis
with the cytosolically-expressed LbADH, the native cellular metabolisms of the host were utilized
for NADPH-regeneration (Scheme 1, II). As a third option, the in-situ NADPH-regeneration utilizing
“helper”-enzymes (Scheme 1, III), such as the glucose 1-dehydrogenase GDH (EC 1.1.1.47) from Bacillus
subtilis subsp. natto (Taxonomy ID: 86029), was explored. In comparison to other NADPH-regeneration
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enzymes, such as formate-/lactate-decarboxylases, GDH does not produce CO2-gas bubbles, which
are detrimental for microfluidic processes.
Scheme 1. NDK 1 reduction employing different methods for NADPH-cofactor regeneration. Note that
for simplicity, only (R)-selective reaction products are shown; for the structure of the corresponding
(S)-selective reaction products, i.e., the syn/anti hydroxyketones 2a/2b and (S,S) pseudo C2-diol 3c
or meso syn/anti diols 3a/3b, see reference [37]. The NADPH cofactor can be regenerated by (I) the
oxidation of isopropanol to acetone; (II) in the case of whole-cell biocatalysis, the host’s native cellular
metabolisms; or (III) an additional “helper”-enzyme such as glucose dehydrogenase (GDH).
As an initial experiment, we tested physisorption of the enzyme of choice to the reactor
surface, because this method was widely applied and simple. To this end, a recently described
polydimethylsiloxane (PDMS) chip design [40] with a meandering flow path of 150 µL total
internal volume was incubated with 10 µM LbADH–SBP enzyme solution overnight at 4 ◦C.
The unbound enzymes were stripped from the reactor wall by continuous perfusion with a PBS
buffer. The temperature was then increased to 30 ◦C and the reactor perfused at a flowrate of
2 µL/min with a substrate solution containing NDK 1, NADP+ cofactor, and 5% (v/v) 2-propanol
for cofactor-regeneration (Scheme 1, I). In order to analyze the NDK-reduction activity of the reactor,
samples from the outflow were analyzed by quantitative chiral HPLC-analysis. We found that the
physisorbed LbADH–SBP in the reactor module was not sufficient to convert NDK 1 (Figure 2a).
We attributed this result to the inefficient immobilization strategy in terms of low binding efficiency
and possible concurrent deactivation of the enzyme. To validate this hypothesis and to increase the
effectiveness of enzyme immobilization on the reactor walls, we employed a procedure for covalent
immobilization by initially coating the PDMS chip with (3-aminopropyl) triethoxysilane (APTES).
The surface-bound amino groups were utilized for covalent immobilization of the LbADH–SBP
surface using glutaraldehyde crosslinking. Indeed, the so-prepared chip showed 15% NDK conversion
to 14% (R)-syn/anti-hydroketone 2c/d with only small amounts (1%) of diol 3d produced (Figure 2a).
Catalysts 2019, 9, 164 5 of 13
Figure 2. Flow biocatalytic conversion of NDK 1 to (R)-syn/anti-hydroketone 2c/d and diol 3d. The bar
graphs show the product distribution obtained from the various different reactor modules, i.e., the
meander channel (a) with physisorbed or chemically immobilized pure enzyme or whole-cell biofilm
intracellularly expressing the LbADH–SBP, (b) the packed-bed reactor with LbADH–SBP and GDH–SBP
immobilized on individual magnetic particles and (c) the all-enzyme LbADH–SC/GDH–ST hydrogel
filled reactor module. All modules were perfused with a substrate solution containing 10 mM NDK 1.
Product distributions were determined by quantitative HPLC analysis. Note that the stereoselectivity
of all reactor modules was determined exclusively by the incorporated LbADH.
In order to relate the results with the purified enzyme in this reactor geometry to a whole-cell
biocatalysis approach, we used a previously developed whole-cell system that would express the
enzyme cytosolically [41]. Here, we used the meander channel to grow 3-dimensional biofilms that
would be capable of utilizing the native NADP(H) regeneration of E. coli (Scheme 1, II). Growth of
the biofilm was achieved by inoculation and initial perfusion of the chip for 24 h before protein
expression was induced by supplementation of the media with IPTG. After another 24 h, NDK 1 was
supplemented to the reaction media to facilitate continuous biotransformation. Productivity of the
biofilm was determined by HPLC analysis. The analysis of the outflow from this reactor module
showed 43% NDK conversion to form 37% (R)-syn/anti-hydroketone 2c/d with up to 6% of the wanted
diol 3d product. This represents a significant improvement of the reactor productivity.
To evaluate the extent to which more complex immobilization processes can lead to improved
productivity in flow biocatalysis, we then investigated a recently described modular packed-bed
reactor setup that contained streptavidin (STV)-functionalized magnetic microparticles to enable
selective one-point immobilization of LbADH–SBP from crude cell lysates [30]. To further
increase the productivity of the reactor we co-immobilized SBP-tagged GDH as a helper enzyme
(Scheme 1, III). As indicated in Figure 2b, the resulting biocatalytic reactor modules showed 98%
NDK conversion predominantly producing the desired diol 3d product (70%) along with 28%
of the (R)-syn/anti-hydroketones 2c/d, when perfused with NDK 1 at a flowrate of 1 µL/min.
Very importantly, this setup enables long operating times of more than five days, thereby indicating
stable enzyme immobilization and general robustness of the reactor [30]. Despite these advantages,
the available volume of the reactor module is far from being optimally used: Taking into account an
enzyme binding capacity of ~10 µg/mg particles [30], the maximal enzyme capacity of the module
can only be 1% (w/w) enzyme per carrier material. This assessment shows that 99% of the available
reactor space is filled with non-catalytic materials.
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Since the incorporation of any type of carrier materials inevitably reduces the amount of
biocatalyst in the reactors, it is evident that the application of carrier-free immobilization strategies
could further increase the productivity of flow reactors. To make better use of the space reserves, we
recently developed self-assembling all-enzyme hydrogels that were produced by genetically encoded
cross-linking of pure enzymes [23]. To this end, the enzymes LbADH and GDH were employed
and genetically fused with either the SpyTag (ST) or the SpyCatcher (SC) [42]. The ST/SC system
enables the rapid cross-linking of the two tetravalent protein building blocks through the formation
of covalent isopeptide bonds under physiological conditions, resulting in the formation of a pure
LbADH–SC/GDH–ST hydrogel. Here, we used this novel biocatalytic material for the loading of
a 150 µL straight flow channel in a microfluidic PDMS chip to generate a hydrogel-reactor module
(Figure 2c). Indeed, this bioreactor enabled the continuous production of the desired diol product 3d
in a purity of >99%, at the same flowrate of 1 µL/min that had been applied to the packed-bed reactor
(Figure 2b).
Given the outstanding productivity of all-enzyme reactor modules, we further investigated
the process stability and productivity of these systems by analyzing the outflow at flowrates from
1–200 µL/min (Figure 3a). Indeed, the concentration of the diol 3d product in the reactor outflow
decreased from >99% at a flowrate of 1 µL/min to 15 ± 3% at 200 µL/min. Remarkably, the hydrogel
reactor still produced substantially higher amounts of the diol 3d even when it was operated at a
flowrate 10 times that of the particle reactor. These results impressively illustrate the high robustness
and catalytic activity of the hydrogel reactor module. The high initial activity of the reactor only
slightly decreased when operated for a prolonged time over five days (Figure 3b). We hypothesize
that the initial slight decrease of the reactor performance was caused by the outflow of unassembled
all-enzyme hydrogel building blocks.
Since the industrial implementation of enzymatic flow processes is difficult when expensive
cofactors (e.g., NADPH) need to be supplemented continuously [43], we also investigated the influence
of the operational flow rate on the product distribution for reactor modules that contained all-enzyme
hydrogels in which NADPH was entrapped during the polymerization step. To this end, the modules
were loaded with all-enzyme hydrogels bearing 1 mM co-entrapped NADP+ and perfused with a
reaction buffer containing only glucose and NDK. Indeed, the NDK was continuously converted
for more than 30 h with only a minor decrease in reactor performance. These results show that the
entrapped NADPH cofactor was effectively retained in the hydrogel matrix to enable the conversion
of more than 120 reactor column volumes (Figure 3c).
For a comparison of the reactor space productivity of the various flow biocatalyst modules, we
compared all of the established systems in terms of volumetric reactor productivity of the diol 3d
product by calculating the respective STY. Figure 4 shows that the various platforms revealed huge
differences in STY. While the systems based on the reactor surface modification with only one layer of
physisorbed or chemically immobilized enzymes resulted in an STY <1 g L−1 day−1, multilayers of
catalytically active biofilms showed an STY of 4.6 g L−1 day−1. Much higher STY values of 102 g L−1
day−1 could be obtained with the particle reactor. We attribute this result to the fact that the introduced
particles increased the available reactor surface by approximately 50 times, thereby increasing the
concomitant enzyme binding capacity. However, the effect of a better utilization of the available reactor
volume was significantly increased by the use of carrier-free self-assembled all-enzyme hydrogels.
In this case, the hydrogel-filled reactor modules showed an STY, 4.5 times higher, of 487 g L−1 day−1.
This clearly demonstrates the advantages of carrier-free immobilization strategies to maximize the STY
of biocatalytic reactors. Considering the diol 3d productivity of the different systems per chip, this
corresponds to a 73-fold increase in chip productivity of the 150 µL hydrogel reactor (73 mg day−1) as
compared to the 10 µl particle reactor (1 mg day−1).
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Figure 3. Product distributions determined in the outflow of reactor modules containing the
LbADH–ST/GDH–SC hydrogel: (a) Flowrate dependency; (b) long-term time dependency with
continuous NADP+-supply over >6 days (flowrate 10 µL/min); (c) time dependency with encapsulated
NADP+ (flowrate 10 µL/min).
In conclusion, for the first time we have provided a comparative study in which different
technical platforms for flow biocatalysis are tested with the same enzyme. The results clearly showed
that self-immobilizing biocatalysts, used either in a purified formulation [23,30] or as whole cell
biocatalysts [41], could be advantageously applied to maximize the STY in flow-reactors. As expected,
the efficient utilization of the available reactor space plays a decisive role. While simple mono- and
multilayer coatings of the reactor surface lead to STY <10, these values can be considerably increased
by using three-dimensional space. Specifically, with packed-bed reactors, values of 100 were achieved.
With room-filling packed hydrogels, values of >450 were achieved. Even without detailed optimization
of the flow and reaction conditions, continuous production for more than six days can be achieved.
Hence, such biocatalytic reactors are, in principle, ready for practical applications. An important issue
is that self-immobilizing biocatalysts can often be employed without extensive purification, thereby
significantly reducing time and costs for process development.
A general advantage for the industrial use of flow biocatalysis with recombinant enzymes is that
the turn-around time from the idea to the final drug product for the market lead could be significantly
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shortened. In the present study, we used the ketoreductase LbADH for stereoselective syntheses
as a proof-of-concept. However, our approach should also be applicable for many other enzymes,
especially when they are cofactor-dependent, such as P450 monooxygenases [44], imine reductases [45],
or transaminases [46]. We therefore anticipate that compartmentalized microfluidic reaction modules
equipped with self-immobilizing biocatalysts could be of tremendous utility for a variety of biocatalytic
and even chemo-enzymatic cascade reactions.
Figure 4. Diol 3d space–time yields (STY) obtained for the various different flow-biocatalysis reactor
modules. Schemes of the chip cross section with the immobilized biocatalyst are shown underneath
the corresponding bar graphs.
3. Materials and Methods
3.1. Cloning of Plasmids
The cloning for all expression plasmids, e.g., for the LbADH and GDH with an SBP-tag [30] or a
His–SC/ST–His-tag [23] was previously described.
3.2. Expression, Purification, and Characterization of Enzymes
The expression, purification, and characterization of the proteins was done as described
before [23,30]. In brief, E. coli BL21(DE3) was transformed with the corresponding expression vector
using electroporation. The freshly transformed E. coli cells harboring the different plasmids were
selected overnight on LB/agar plates containing 100 µg/mL ampicillin at 37 ◦C. Liquid cultures of
20 mL LB medium containing ampicillin were prepared from the LB/agar plates overnight cultures.
The 20 mL cultures were incubated for 14–18 h at 37 ◦C, 180 rpm in a 150 mL shaking flask and
then transferred in 2 L LB-medium containing ampicillin in 4 L shaking flasks and incubated at
37 ◦C, 180 rpm until the OD600 reached a value of 0.6. The temperature was then lowered to 25 ◦C
and IPTG was added to a final concentration of 0.1 mM for an additional 16 hours. The cells were
harvested by centrifugation (10,000 x g, 10 min) and resuspended in 30 mL buffer A (50 mM NaH2PO4,
300 mM NaCl, 1 mM MgCl2, 10 mM Imidazole, pH 8.0). After disruption by ultrasonication, the
cell lysate was obtained by centrifugation (45,000 x g, 1 h), filtered through a 0.45 µm Durapore
PVDF membrane (Steriflip, Millipore) and loaded on a HisTrap FF (5 mL) Ni–NTA column (GE
Healthcare, Freiburg, Germany) mounted on an Äkta Pure liquid chromatography system (GE
Healthcare, Germany). The column was washed with 50 mL buffer A and the 6 x His-tagged proteins
were eluted with 100% buffer B (50 mM NaH2PO4, 300 mM NaCl, 500 mM Imidazole, pH 8.0).
For purification of SBP-tagged proteins, a 5 mL Strep-Tactin®Superflow®cartridge (iba-lifescience,
Göttingen, Germany) was used according to the manufacturer’s instructions. Subsequently, the
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buffer was exchanged for the SBP-tagged GDH and LbADH to 100 mM Triethanolamine pH 7.5,
1 mM MgCl2 (TEA-Mg), and for GDH–ST and LbADH–SC to 100 mM KPi pH 7.5 by Vivaspin 10,000
MWCO (GE Healthcare). The purity of the recombinant, purified proteins was analyzed by standard
discontinuous SDS-polyacrylamide Laemmli-midi-gels visualized by Coomassie staining [23,30].
The protein concentrations were determined by UV-Vis spectroscopy, using the theoretical molar
extinction coefficients at 280 nm, as calculated by the Geneious version 8.0.5 software [47]. All enzyme
activities were in agreement with earlier publications [23,30].
3.3. Fabrication of the PDMS Chips
The microfluidic PDMS chips were produced as previously described [40]. In brief, the chip
designs were based on the dimension of standard microscope glass slides (76 × 26 mm2 DIN ISO
8037-1:2003-05). The upper part containing the reaction channel was manufactured by a replica casting
of PDMS (Sylgard 184, Dow Corning, Midland, MI, USA) in brass replication molds. Both the meander
and linear-shaped channels had a total volume of approximately 150 µL. The meandering channel
had a rectangular cross section of 500 × 1000 µm2, resulting in a reactor surface of 304 mm2, whereas
the linear channel used for hydrogel immobilization was 3 mm wide, 1 mm high and 54 mm long,
resulting in a reactor surface of 178 mm2. Cannulas (Sterican, B. Braun Melsungen AG, Melsungen,
Germany), were inserted through horizontal holes in the molds before pouring the PDMS prepolymer
to serve as placeholders for the cannulas. The PDMS was cured at 60 ◦C for at least 3 h. Except for the
PDMS chips that were filled with the hydrogel (see 3.7), all PDMS chips were sealed with standard
microscope glass slides. To this end, a freshly prepared chip and acetone-cleaned glass slides were
plasma-activated in a PlasmaFlecto 10 machine (Plasma technology GmbH, Herrenberg, Germany).
Thereafter, the activated surfaces of the PDMS chip and the glass slide were pressed together for
covalent binding and subsequently incubated for 15 min at 100 ◦C.
3.4. Preparation and Analysis of Reactor Modules Containing Physisorbed or Chemically Immobilized Enzymes
Chemical immobilization on the meandering PDMS/glass chips was performed following a
previously described protocol [48]. For initial cleaning of the chip surface, a piranha solution (seven
parts concentrated sulfuric acid, one part 30% hydrogen peroxide solution) was injected into the
chip and incubated for 5 min. Thereafter, the channel was washed for 15 min until the pH was
neutral with ddH20 at a flow rate of 1 mL/min, then for 5 min with 99% EtOH and subsequently for
15 min with ddH20. For the amino-modification the flow channel was filled and incubated with a 10%
(3-aminopropyl) triethoxysilan (APTES) solution for 15 min, which was flushed out afterwards with six
channel volumes of 100 mM PBS (100 mM KH2PO4/K2HPO4, 150 mM NaCl, 1mM MgCl2, pH = 7.5)
at a flow rate of 500 µL/min. The channel was then filled with a 50% (w/v) aqueous glutaraldehyde
solution for 15 min, washed with six channel volumes of PBS and finally incubated with a 10 µM
LbADH–SBP in PBS for 15 min.
For the preparation of PDMS/glass chips with physisorbed enzymes, untreated chips were
incubated overnight at 4 ◦C with a 10 µM LbADH–SBP solution. The enzyme-functionalized chips
were subsequently washed for 45 min with PBS at a flow rate of 10 µl/min.
To evaluate the catalytic activity, the enzyme functionalized flow chips were placed on the deck
of a microfluidic work station and incubated at 30 ◦C. Syringe pumps with a reaction buffer (10 mM
NDK 1, 1 mM NADP+, 5% (v/v) 2-propanol in PBS) were connected via polytetrafluorethylen (PTFE)
tubing and the reactions were carried out, unless otherwise stated, at 2 µL/min perfusion flowrate.
Samples were drawn from the reactor with a previously described autosampler [40] and subsequently
analyzed by chiral HPLC as previously described [37].
3.5. Preparation and Analysis of Catalytically Active E. coli Biofilm Reactor Modules
Experiments with catalytically active biofilms were performed as previously described [40].
In brief, E. coli BL21 (DE3) cells were transformed with the plasmid pET_LbADH–SBP [30] and
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cultivated for 24 h at 37 ◦C in LB medium, containing 100 µg/mL ampicillin, to form a biofilm
inside the meandering PDMS/glass chip. The temperature was then reduced to 30 ◦C and the
protein production was induced by an addition of 0.5 mM ITPG to the perfused cultivation medium.
After 24 h, the biofilm populated flowcells were perfused with reaction media containing 10 mM
NDK 1 at a flowrate of 2 µL/min. Sampling and analysis of the reactor productivity was conducted as
described above (see 3.4).
3.6. Preparation and Analysis of Microparticle Packed-Bed Modules Containing SBP-Tagged Enzymes
Preparation of the particle reactor was done as previously described [30]. In brief, magnetic
Dynabeads M-280 Streptavidin (MB-STV) from Thermo Fisher Scientific were used for immobilization
of the SBP-tagged enzymes. The MB-STV were mixed with 1 nmol of the purified SBP-tagged
protein/mg MB for 30 min, 30 ◦C at a tube rotator. The MB-STVs were subsequently washed three times
with TEA-Mg and supplemented with 0.01% (v/v) Tween20 (TEA-T-Mg). The enzyme-functionalized
MB-STVs were loaded into the individual compartments of a polymethylmethacrylate (PMMA)
chip (microfluidic chipshop, Jena, Germany) comprising four linear flow channels that could be
connected with each other by PTFE tubing. Filling of the compartments was achieved through a
Mini luer-to-pipette adapter and a corresponding loaded pipette tip using a negative flowrate of
−50 µL/min. The dimensions of one channel were 58.5 × 1 × 0.2 mm, which corresponded to a
reactor volume of 11.7 µL. The magnetic/catalytic zone, which was deteremined by Nd magnets
arranged underneath, had a volume of approximately 10 µL, respectively 7 µL when 4.5 mg beads
were loaded (10 mg corresponded to ~6–7 × 108 beads with a diameter of 2.7 µm). With an average
size of 22.9 µm2/particle, the particle loading increased the total reactor surface from approximately
140 mm2 (empty) to 6700 mm2. Filled channels were connected with a short PTFE tubing (internal
diameter 0.5 mm) using Mini luer plugs (microfluidic chipshop). The same tubing and plugs were
used to connect the inlet of the assembled chip with a CETONI neMESYS base module holding the
syringe pump containing the cofactor/substrate solution and the outlet with the CETONI Compact
Positioning System rotAXYS, which was controlled by the QmixElements software Qt 5.9.2. (Version:
20180626, CETONI GmbH, Korbussen, Germany). The HT200 temperature-controlled chipholder (ibidi
GmbH, Planegg, Germany) was set to hold 30 ◦C. The chipholder was modified with Nd permanent
magnets, positioned beneath the channels of the chip. The syringe pump was filled with a 5 mL
cofactor/substrate solution containing 5 mM NDK 1 in TEA-T-Mg, and 1 mM NADP+ supplemented
with 0.01% sodium azide to avoid fouling. For cofactor regeneration, the reaction buffer was either
complemented with 5% (v/v) 2-propanol or 100 mM glucose. A flow rate of 1 µL/min was used.
The chip outflow was automatically fractionated by the rotAXYS system in a 96-well plate which
contained 50 µL 7 M NaClO to stop all enzymatic reactions. The samples were subsequently analyzed
by chiral HPLC.
3.7. Preparation and Analysis of Hydrogel Reactor Modules
Preparation and analysis of the hydrogel reactor was achieved as previously described [23].
In brief, PDMS chips with a linear channel were placed inside an incubator 1000 (Heidolph, Germany,
set to 30 ◦C), filled with 150 µL protein solution of 1000 µM GDH–ST-His/His-SC–LbADH in KPi-Mg
(100 mM KPi pH 7.5, 1 mM MgCl2) and incubated for 30 min. For experiments with gel-entrapped
NADP+, the protein solution was supplemented with 1 mM NADP+. This process was repeated
three times and the PDMS chips were then sealed with a glass slide or with a polyolefin foil
(HJ-BIOANALYTIK GmbH, Erkelenz, Germany). The NADP+-encapsulating hydrogels contained
NADP+ at a final concentration of 10 µM. A pumping unit (Fusion 100, Chemyx Inc., Stafford, TX,
USA) with two independent syringe modules equipped with 5 or 20 mL Omnifix syringes (B. Braun
Melsungen AG, Melsungen, Germany) was connected to the chip for perfusion of reaction media at a
flowrate of 10 µL/min. The syringes were filled with 5–10 mL substrate solution containing 5 mM
NDK 1, 100 mM glucose in KPi-Mg, supplemented with 0.01% (v/v) sodium azide to avoid fouling,
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and 0 or 1 mM NADP+ depending on the individual experiment. The chip outflow was connected to
the Compact Positioning System rotAXYS360 (CETONI GmbH, Korbussen, Germany) to allow for
automatic fractioning into 96-well plates. The samples were subsequently analyzed by chiral HPLC.
3.8. Chiral HPLC Analysis
Synthesis and the characterization of NDK 1 as well as the analysis of biocatalytic reaction
products by chiral HPLC were performed as previously described [37]. In brief, ethyl acetate extractions
from the crude reaction mixtures (described above) were dried and resuspended in 100 µL of the
mobile phase (90% n-heptane, 10% 2-propanol) and 10–30 µL of the solution was analyzed by HPLC
(Agilent 1260 series HPLC equipped with a Diode Array Detector (210 nm) on a Lux 3µ Cellulose-1
(150 × 2.00 mm) chiral column (Phenomenex)). Specific running conditions were used for the analysis
of the hydroxy ketones 2 (method A: Chromatography solvent 90% n-heptane/10% 2-propanol, 10 min
isocratic, column oven temperature of 10 ◦C and a flowrate of 0.5 mL/min) and for diol 3 (method B:
Chromatography solvent 98% n-heptane/2% 2-propanol, 20 min isocratic, column oven temperature
of 45 ◦C and a flowrate of 1.0 mL/min).
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